Resistance of mice vaccinated with rabies virus internal structural proteins to lethal infection.
Mice were vaccinated with recombinant vaccinia virus (rVac) expressing the glycoprotein (G), nucleoprotein (N), phosphoprotein (NS) or matrix protein (M) of rabies virus and their resistance to peripheral lethal infection with street rabies virus was examined. Mice vaccinated with rVac-G or rVac-N developed strong antibody responses to the corresponding proteins and essentially all mice survived challenge infection. Mice vaccinated with rVac-NS or rVac-M developed only a slight antibody response, however, a significant protection (59%) was observed in the rVac-NS-vaccinated mice, whereas rVac-M-vaccinated mice were not protected. No anti-G antibodies were detected in the sera of mice which has been vaccinated with rVac-N or rVac-NS and survived challenge infection. Passive transfer of anti-N monoclonal antibodies (MAbs) recognizing an epitope located on amino acids 1-224 of the protein prior to challenge resulted in significant protection, although the protection was not complete even with a high amount of antibodies. In contrast, none of the mice given MAbs recognizing an epitope of amino acids 247-415 or F(ab')2 fragments from a protective MAb IgG were protected. Administration of anti-CD 8 MAb to rVac-N-vaccinated mice showed no significant effect on protection. Our observations suggest that a considerable part of the protection achieved by the vaccination with rVac-N can be ascribed to the intact anti-N antibodies recognizing an epitope located on amino acids 1-224 of the protein.
Takita-Sonoda
Y
Y
Department of Microbiology, Oita Medical University, Japan.
Fujii
H
H
Mifune
K
K
Ito
Y
Y
Hiraga
M
M
Nishizono
A
A
Mannen
K
K
Minamoto
N
N
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology; D000914:Antibodies, Viral / Q000008:administration & dosage / Q000096:biosynthesis; D001483:Base Sequence; D016827:CD8 Antigens / Q000276:immunology; D002213:Capsid / Q000008:administration & dosage / Q000276:immunology; D002478:Cells, Cultured; D006224:Cricetinae; D004279:DNA, Viral; D007113:Immunity, Innate; D007116:Immunization, Passive; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D011817:Rabbits; D011818:Rabies / Q000517:prevention & control*; D011819:Rabies Vaccines / Q000008:administration & dosage* / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology; D014616:Vaccinia virus / Q000235:genetics; D014758:Viral Core Proteins / Q000008:administration & dosage / Q000276:immunology; D014763:Viral Matrix Proteins / Q000008:administration & dosage / Q000276:immunology; D017361:Viral Nonstructural Proteins / Q000008:administration & dosage / Q000276:immunology; D015678:Viral Structural Proteins / Q000008:administration & dosage / Q000276:immunology*
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D016827:CD8 Antigens; D004279:DNA, Viral; D011819:Rabies Vaccines; D014614:Vaccines, Synthetic; D014758:Viral Core Proteins; D014763:Viral Matrix Proteins; D017361:Viral Nonstructural Proteins; D015678:Viral Structural Proteins